Xilio Therapeutics, Inc. (XLO) financial statements and ratios from SEC XBRL: revenue $43.77M (TTM), net margin -80.1%, revenue growth 131.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $43.77M |
| Net Margin | -80.1% |
| Revenue Growth (YoY) | 131.2% |
| EPS Growth (YoY) | 106.3% |
| FCF Growth (YoY) | 26.2% |
| Price / Book | 0.73 |
| Price / Sales | 0.82 |
| FCF Yield | -116.3% |
| Altman Z-Score | -3.45 (distress) |
| Sector P/E (Healthcare) | 21.7 |
XLO overview · XLO earnings · XLO KPIs · XLO investor relations · XLO ownership · XLO peers · XLO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.